Antimicrobial resistance (AMR) is fast becoming one of the most serious threats to modern medicine, with new global evidence showing that bacteria and fungi are developing resistance faster than current therapies can keep pace. A comprehensive international review of surveillance and clinical data has flagged AMR as a slow-moving pandemic, one that carries significant implications for India’s pharmaceutical industry, healthcare system, and public health priorities.

A growing global and regional concern

The analysis draws on data from major international surveillance platforms to map resistance trends across regions. Pathogens such as Escherichia coli and Klebsiella pneumoniae continue to dominate infection burdens worldwide, with widespread resistance to β-lactam antibiotics reported across large parts of Asia. Alarmingly, resistance to carbapenems, considered last-line therapies, is increasing in multiple geographies, including Europe and the Americas.

Highly drug-resistant hospital pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa are proving particularly difficult to manage, with resistance rates crossing 70% in certain regions. In contrast, countries with strong antimicrobial stewardship frameworks, particularly in northern Europe, continue to report significantly lower resistance levels, highlighting the impact of policy and regulation.

Fungal resistance adds another layer of risk

The review also underscores the rising threat of antifungal resistance. Candida auris, now reported across continents, is emerging as a near pan-resistant pathogen, while Aspergillus fumigatus is showing increasing resistance to azole antifungals. The role of agricultural fungicide use in accelerating resistance adds complexity to the challenge, reinforcing the need for a One Health approach.

Implications for Indian pharma

For India, one of the world’s largest producers and consumers of antibiotics, the findings are particularly significant. While Indian pharma plays a critical role in ensuring global access to affordable antimicrobials, the review reinforces the urgent need to shift from volume-driven antibiotic use to precision-guided therapy and innovation-led R&D.

The authors highlight combination therapies, β-lactamase inhibitors, polymyxin-based regimens, and pharmacokinetic-pharmacodynamic (PK-PD) guided dosing as key tools in extending the life of existing drugs. These approaches open opportunities for Indian companies to strengthen portfolios in complex generics, novel combinations, and differentiated formulations, while also investing in next-generation antimicrobials.

Beyond drugs: systems, data, and stewardship

AMR is no longer viewed solely as a clinical problem. Weak surveillance systems, over-the-counter antibiotic sales, and inconsistent prescription practices, challenges still present in many developing markets, are accelerating resistance. The review calls for tighter regulation, responsible antibiotic use in agriculture, and the adoption of genomic diagnostics and AI-enabled clinical decision tools in hospitals.

Also read: Early-Stage Nipah Virus Vaccine Trials Signal Progress in Pandemic Preparedness

The road ahead

The message for industry and policymakers is clear: combating AMR will require coordinated global action, smarter use of existing therapies, and sustained investment in innovation. For Indian pharma, this moment represents both a warning and an opportunity to lead in responsible antibiotic development, support stewardship initiatives, and help safeguard the foundations of modern medicine in India and beyond.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!